相关文档

• 182-00777.docx

  Aprehensive Safety Analysis of 6026 Patients from Phase 2 and 3 Short and Long Term Clinical Trials with Evolocumab (AMG 145) Peter P Toth1, Naveed Sattar2, Jacques Genest3, Olivier Descamps4, R

• 182-00787.docx

  Efficacy and Safety of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients With Type 2 Diabetes Naveed Sattar,1 C Stephen Djedjos,2 Jennifer G Robinson,3 David Preiss,1 Mary Elliott,4 Ransi Somarat

• 182-00877.docx

  Waist-to-Height Ratio and Triglycerides/High-Density Lipoprotein Cholesterol Were the Optimal Predictors of Metabolic Syndrome in Uighur Men and Women in Xinjiang, ChinaBang-Dang Chen, PhD,1,* Yi-Ni

• 182-00775.docx

  LDL Cholesterol Reduction in Elderly Patients with the PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of 1779 Patients in Phase 2, 3 and Open Label Extension StudiesMichael J Kore

• 185-00770.docx

  Naoxintong Improves Perfusion through Promoting Neovascularization in Hind-limb Ischemia Model of ApoE-/- Mice Fed with High-fat DietZhen Dong1,2, Hong zhu2, Xiaolei Sun2, Peng Wang2, Xiaona Zhao2,

• 172-00757.docx

  吸烟与冠心病严重程度的关系目的：探讨吸烟与冠心病的发病及预后之间的关系。方法：回顾性分析我院2014年1月至2014年12月1593例临床诊断为冠心病患者分为三组,无吸烟组857例,已戒烟组231例,在吸烟组505例。通过分析三组间患者的一般情况、冠状动脉造影以及主要不良心脑血管事件发生率等方面的异同,探讨吸烟与冠心病的发病及预后之间的关系。结果：无吸烟组、已戒烟组、在吸烟组三组间年龄、诊断差

• 184-00077.ppt

  Should I simultaneously treat diseased left main trunk during primary PCI for proximal LAD Hesitation may make ainformation53 year-old maleVisited emergency department for severe chest pain at restEC

• 182-183.ppt

  #

• 182-183.ppt

  #

• 181-182.ppt

  #